Resources from the same session
Welcome and introduction
Presenter: Noemi Reguart Aransay
Session: ESMO Colloquium supported by Eli Lilly and Company: Integrating molecular oncology in the care of patients with rare oncogene-driven non-small cell lung cancer
Resources:
Slides
Webcast
The importance of next-generation sequencing (NGS) testing in non-small cell lung cancer: Science, implementation and timing
Presenter: Albrecht Stenzinger
Session: ESMO Colloquium supported by Eli Lilly and Company: Integrating molecular oncology in the care of patients with rare oncogene-driven non-small cell lung cancer
Resources:
Slides
Webcast
Targeting molecular aberrations beyond EGFR, ALK: Clinical evidence for efficacy and ongoing research
Presenter: Jürgen Wolf
Session: ESMO Colloquium supported by Eli Lilly and Company: Integrating molecular oncology in the care of patients with rare oncogene-driven non-small cell lung cancer
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: ESMO Colloquium supported by Eli Lilly and Company: Integrating molecular oncology in the care of patients with rare oncogene-driven non-small cell lung cancer
Resources:
Webcast
Concluding remarks
Presenter: Jürgen Wolf
Session: ESMO Colloquium supported by Eli Lilly and Company: Integrating molecular oncology in the care of patients with rare oncogene-driven non-small cell lung cancer
Resources:
Webcast